• Science and Research

  CF Lung Infection Therapy AR-501 Granted FDA Orphan Drug Status

  Posted by cystic-fibrosis-news-moderator on July 8, 2019 at 9:11 am

  

  Aridis Pharmaceuticals’ AR-501, an inhaled formulation of gallium citrate for chronic lung infections, was granted the FDA’s orphan drug status. Read more here.

  What do you think of this news?

  cystic-fibrosis-news-moderator replied 4 years, 9 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply